Notable examples include nusinersen (Spinraza), a ssASO approved in 2016 for the treatment of spinal muscular atrophy (SMA), which corrects SMN2 splicing to increase the production of the survival motor neuron (SMN) protein [251,252]. Here, SMN2 is linked to spinal muscular atrophy.